Overview
My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.
For more information see http://ed-media.mc.duke.edu/BMT.nsf
For more information see http://ed-media.mc.duke.edu/BMT.nsf
Current Duke Appointments & Affiliations
Donald D. and Elizabeth G. Cooke Cancer Distinguished Research Professor
·
2002 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Professor of Medicine
·
2001 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Professor in Integrative Immunobiology
·
2001 - Present
Integrative Immunobiology,
Basic Science Departments
Professor in Pathology
·
2011 - Present
Pathology,
Clinical Science Departments
Research Professor of Global Health
·
2018 - Present
Duke Global Health Institute,
University Institutes and Centers
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Chief, Division of Cell Therapy in the Department of Medicine
·
2004 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Scholarly Works
CaMKK2 Expression Correlates with High-Risk CLL Biology, and Pharmacologic Inhibition Is Associated with Reduced Leukemic Cell Survival and Nurse-like Cell Support In Vitro.
Journal article Cells · July 20, 2026 BACKGROUND/OBJECTIVES: Chronic lymphocytic leukemia (CLL) is characterized by clinical and biological heterogeneity shaped by intrinsic signaling programs and microenvironmental interactions. Established biomarkers, including IGHV mutation status and TP53 ... Full text Open Access Link to item CiteSociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteImpact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteRecent Grants
Hematology & Transfusion Medicine
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 20312/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Center for Advancing Translational Sciences · 2025 - 2030The Gut Microbiome and Development of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Children
ResearchCo-Mentor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education
Yale University ·
1981
M.D.